光子计数探测器4D CT在原发性甲旁亢术前定位中的应用
本研究评估光子计数探测器CT(PCD-CT)行4D甲状旁腺成像对原发性甲状旁腺功能亢进患者术前定位的价值。36例患者术前接受4D PCD-CT并与手术病理对照,同时与超声和锝-99m甲氧异腈显像比较。PCD-CT对36/36例患者均正确检出异常甲状旁腺组织,对7例异位腺瘤全部定位成功。
要点
- PCD-CT对全部36例均正确定位异常甲状旁腺,定位率显著高于超声及核素显像。
- PCD-CT对异位腺瘤全部7/7定位,优于超声3/7和显像4/7。
- PCD-CT定位了8例超声和显像均未检出的病灶,多数位于下位或异位,阅片需重点排查这些区域。
核心结论
- 光子计数4D CT对原发性甲旁亢异常甲状旁腺术前定位显示100%患者水平定位率,尤其在异位腺瘤中表现突出。
研究设计与样本
- 经IRB批准的双向性研究,纳入36例原发性甲状旁腺功能亢进患者,均行术前4D PCD-CT并接受甲状旁腺切除术。
- 超声和锝-99m甲氧异腈显像分别有34例和33例可获取,由3名接受专科培训的放射科医生盲法独立阅片,每名医生仅评估一种模态。
- 以手术及组织病理结果作为参考标准,患者水平定位率采用双侧95%精确二项分布置信区间汇总。
关键影像表现/征象
- PCD-CT定位的8例超声或显像未识别病灶中,多数位于下位或异位,提示阅片时需重点检查下位及异位区域。
- 全部7例异位腺瘤均由PCD-CT定位,影像阅片时对异位甲状旁腺腺瘤需扩大搜索范围至胸骨后、纵隔等区域。
诊断标准与关键数值
- PCD-CT在36/36例患者中正确定位异常甲状旁腺组织,定位率为100%,95%CI为90.3%至100%。
- 超声检出经手术证实的明确病灶为12/34例,定位率35%,95%CI为19.7%至53.5%;包含经证实的可疑病灶后为16/34例,47%,95%CI为29.8%至64.9%。
- 锝-99m甲氧异腈显像检出经手术证实的明确病灶为19/33例,定位率57%,95%CI为39.2%至74.5%;包含经证实的可疑病灶后为23/33例,70%,95%CI为51.3%至84.4%。
临床应用与阅片要点
- 在日常报告中对超声或核素显像阴性或仅见可疑病灶的原发性甲旁亢患者,可考虑建议4D PCD-CT进一步定位。
- 阅片时应特别关注下位甲状旁腺及异位区域,因PCD-CT额外检出的病灶多数位于这些部位。
局限性
- 本研究为单中心研究,样本量为36例,不同模态间比较为描述性分析,未报告统计学检验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND PURPOSE: Accurate preoperative localization of abnormal parathyroid tissue is essential for successful minimally invasive parathyroidectomy. Conventional imaging with ultrasound and Tc-99m sestamibi scintigraphy can be limited, particularly in ectopic disease. This study evaluated the performance of photon-counting detector CT (PCD-CT) for 4D parathyroid imaging in patients with primary hyperparathyroidism.
MATERIALS AND METHODS: In this IRB-approved ambispective study, 36 patients with primary hyperparathyroidism underwent preoperative 4D PCD-CT followed by parathyroidectomy. Ultrasound and sestamibi scintigraphy were available in 34 and 33 patients, respectively. Three blinded fellowship-trained radiologists independently reviewed imaging studies, with each reader assigned to a single modality. Imaging findings were compared with operative and histopathologic results, which served as the reference standard. Patient-level localization rates were summarized with two-sided 95% exact binomial confidence intervals; comparisons among modalities were descriptive.
RESULTS: PCD-CT correctly localized abnormal parathyroid tissue in 36/36 patients (100%; 95% CI, 90.3%-100%). Ultrasound demonstrated surgically confirmed definite lesions in 12/34 patients (35%; 95% CI, 19.7%-53.5%), increasing to 16/34 (47%; 95% CI, 29.8%-64.9%) when confirmed equivocal findings were included. Sestamibi scintigraphy demonstrated definite surgically confirmed lesions in 19/33 patients (57%; 95% CI, 39.2%-74.5%); confirmed localization increased to 23/33 (70%; 95% CI, 51.3%-84.4%) when equivocal findings were included. PCD-CT localized lesions in 8 patients not identified by ultrasound or scintigraphy, most of which were inferior or ectopic. All 7 ectopic adenomas were localized by PCD-CT, compared with 3/7 by ultrasound and 4/7 by scintigraphy.
CONCLUSIONS: Photon-counting 4D CT demonstrated promising high localization rate for preoperative localization of abnormal parathyroid glands in primary hyperparathyroidism, particularly with ectopic adenomas.
引用
- Huls, Burkett, Yu, et al. Photon-Counting Detector 4D CT for Preoperative Localization in Primary Hyperparathyroidism. AJNR Am J Neuroradiol. 2026. PMID: 42580858. doi:10.3174/ajnr.A9583
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。